6. Hims & Hers Health Inc. (NYSE:HIMS)
Hims & Hers Health Inc. (NYSE: HIMS) ranks sixth after rising 10.27 percent to close at $25.88, extending its winning streak to three consecutive trading sessions.
The rally followed a series of analyst upgrades triggered by renewed collaboration between the company and pharmaceutical giant Novo Nordisk. The partnership development helped resolve legal disputes related to compounded versions of popular GLP-1 drugs used for weight loss and diabetes treatment.
Several major investment banks responded by raising their price targets. Deutsche Bank lifted its target to $28, Citigroup increased its forecast to $24, and Bank of America raised its projection to $23.
The telehealth platform has built a rapidly growing business by providing consumers with access to prescription medications, health consultations, and digital healthcare services. In recent years, demand for telemedicine has accelerated as patients increasingly seek convenient healthcare solutions delivered through online platforms.
Under the renewed agreement, Hims & Hers will discontinue the sale and marketing of compounded versions of Novo Nordisk’s drugs Wegovy and Ozempic. However, the company will still offer GLP-1 access in cases where patients cannot be served by the FDA-approved versions and a healthcare provider determines a compounded product is medically necessary.
For investors tracking telehealth stocks and digital healthcare companies, Hims & Hers represents a growing segment of the healthcare industry where technology platforms are transforming how medical services are delivered.
YOU MUST READ THIS: Top 10 Energy Stocks Gaining This Week as Oil Prices Surge.
Click next to see the following stock...
